All news

BSX EPS misses by $0.02, guidance falls below consensus

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

Boston Scientific (NYSE: BSX) reported third-quarter EPS of $0.73, missing analyst estimates by $0.02, but revenue topped expectations at $5.14 billion against a consensus of $5.12 billion. The company also provided guidance for Q4 2026 and FY 2026 EPS, both falling below current analyst consensus estimates. Over the past year, Boston Scientific's stock has decreased by 55.07%.

Read original source

BSX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.